Advancing Reperfusion Therapy for Ischemic Stroke: Direct Transfer to Angiography Suite for Patients With Suspected Large Vessel Occlusion

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Direct Transfer to Angiography Suite (DTAS) for Patients With Suspected Large Vessel Occlusion

The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.

Inclusion Criteria:

• Age≥18 years old;
• Patients presenting with symptoms or signs suggestive of acute large vessel occlusion (LVO) stroke；
• Randomization within 6 hours of symptom onset；
• Baseline NIHSS score ≥10 points prior to randomization;
• Pre-stroke modified Rankin Scale (mRS) score ≤2;
• Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

• Refusal of endovascular treatment；
• Allergy to contrast agents;
• Clinical symptoms or signs suggestive of intracranial hemorrhage (e.g., severe headache, seizures, or signs of increased intracranial pressure);
• Transferred patients (e.g., from centers without thrombectomy capability);
• Seizure at stroke onset, postictal paralysis, or inability or unwillingness to cooperate due to epilepsy or other neurological or psychiatric disorders;
• Clinically unstable conditions requiring urgent life-support treatment;
• Other standard contraindications to endovascular treatment;
• Any terminal illness such that the patient would not be expected to survive more than 1 year;
• Pregnant women, nursing mothers, or women with a positive pregnancy test at admission;
• Unlikely to adhere to the trial protocol or follow-up;
• Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
• Participation in other interventional clinical trials within the previous 3 months.